fasudil has been researched along with Cirrhosis, Liver in 7 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fasudil has the potential to prevent liver fibrosis by activating natural killer cells and inhibiting the proliferation of hepatic stellate cells." | 1.62 | Therapeutic potentials of fasudil in liver fibrosis. ( Xi, Y; Xu, PF, 2021) |
| "Fasudil inhibits liver fibrosis by activating NK cells and blocking hepatic stellate cell activation, thereby providing a feasible solution for the clinical treatment of liver fibrosis." | 1.62 | Fasudil prevents liver fibrosis ( Guo, QJ; Han, QJ; Mu, YL; Su, YH; Zhang, J; Zhao, HJ; Zhao, RR, 2021) |
| "Ursolic acid (UA) is a traditional Chinese medicine with anti-fibrotic effects, but the molecular mechanism underlying these effects is still unclear." | 1.56 | Ursolic acid reverses liver fibrosis by inhibiting interactive NOX4/ROS and RhoA/ROCK1 signalling pathways. ( Huang, C; Liu, C; Luo, F; Luo, Q; Wan, S; Zhu, X, 2020) |
| "Treatment with fasudil or captopril suppressed not only the inflammation reaction but also the accumulation of the extracellular matrix due to the downregulation of TGF-β1 and MMP-9/TIMP-1, which induces the amelioration of the liver fibrosis with diabetes." | 1.48 | Fasudil alleviates hepatic fibrosis in type 1 diabetic rats: involvement of the inflammation and RhoA/ROCK pathway. ( Chu, L; Huo, M; Ma, ZH; Song, T; Wang, N; Xie, Y; Zhang, JP; Zhang, Y; Zhang, YY, 2018) |
| "A rat model of type 2 diabetes was established by high fat diet combined with streptozotocin (30 mg/kg, intraperitoneal injection)." | 1.40 | Fasudil hydrochloride hydrate, a Rho-kinase inhibitor, ameliorates hepatic fibrosis in rats with type 2 diabetes. ( Deng, Y; Fang, C; Meng, F; Wang, M; Zhang, L; Zhou, H, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Xi, Y | 1 |
| Xu, PF | 1 |
| Zhou, W | 1 |
| Yang, Y | 1 |
| Mei, C | 1 |
| Dong, P | 1 |
| Mu, S | 1 |
| Wu, H | 1 |
| Zhou, Y | 1 |
| Zheng, Y | 1 |
| Guo, F | 1 |
| Yang, JQ | 1 |
| Wan, S | 1 |
| Luo, F | 1 |
| Huang, C | 1 |
| Liu, C | 1 |
| Luo, Q | 1 |
| Zhu, X | 1 |
| Han, QJ | 1 |
| Mu, YL | 1 |
| Zhao, HJ | 1 |
| Zhao, RR | 1 |
| Guo, QJ | 1 |
| Su, YH | 1 |
| Zhang, J | 1 |
| Xie, Y | 1 |
| Song, T | 1 |
| Huo, M | 1 |
| Zhang, Y | 1 |
| Zhang, YY | 1 |
| Ma, ZH | 1 |
| Wang, N | 1 |
| Zhang, JP | 1 |
| Chu, L | 1 |
| Fukuda, T | 1 |
| Narahara, Y | 1 |
| Kanazawa, H | 1 |
| Matsushita, Y | 1 |
| Kidokoro, H | 1 |
| Itokawa, N | 1 |
| Kondo, C | 1 |
| Atsukawa, M | 1 |
| Nakatsuka, K | 1 |
| Sakamoto, C | 1 |
| Zhou, H | 1 |
| Fang, C | 1 |
| Zhang, L | 1 |
| Deng, Y | 1 |
| Wang, M | 1 |
| Meng, F | 1 |
7 other studies available for fasudil and Cirrhosis, Liver
| Article | Year |
|---|---|
Therapeutic potentials of fasudil in liver fibrosis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Hepatic Stellate Cells; Humans; Killer Cells, Natural | 2021 |
Inhibition of Rho-Kinase Downregulates Th17 Cells and Ameliorates Hepatic Fibrosis by
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cell Differentiation; Collagen Type I; Femal | 2019 |
Ursolic acid reverses liver fibrosis by inhibiting interactive NOX4/ROS and RhoA/ROCK1 signalling pathways.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acetophenones; Animals; Carbon Tetrachloride; Disease | 2020 |
Fasudil prevents liver fibrosis
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Hepatic Stellate Cells; Killer Cells, Natura | 2021 |
Fasudil alleviates hepatic fibrosis in type 1 diabetic rats: involvement of the inflammation and RhoA/ROCK pathway.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Diabetes Mellitus, Experimental; Diabetes Me | 2018 |
Effects of fasudil on the portal and systemic hemodynamics of patients with cirrhosis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Aged; Animals; Arterial Pressure; Female; Hear | 2014 |
Fasudil hydrochloride hydrate, a Rho-kinase inhibitor, ameliorates hepatic fibrosis in rats with type 2 diabetes.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Connective Tissue Growth Factor; Diabetes Me | 2014 |